Personalized Breast Cancer Trial: Neoadjuvant Therapy
TEODOR Trial: Pioneering Personalized Endocrine Therapy for Early-Stage Breast Cancer
Table of Contents
A groundbreaking clinical trial, ABCSG 61, also known as TEODOR, is set to redefine teh treatment landscape for early-stage, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. This innovative study aims to determine if a notable portion of patients can safely forgo customary chemotherapy by leveraging endocrine responsiveness and circulating tumor DNA (ctDNA) status to guide neoadjuvant therapy.
Optimizing Treatment Through Personalized Medicine
The TEODOR trial represents a significant shift towards personalized medicine in oncology, moving away from a one-size-fits-all approach. By identifying patients who are likely to respond well to endocrine therapy alone, the study seeks to improve treatment efficacy while minimizing the debilitating side effects associated with chemotherapy. This personalized strategy holds the potential to enhance the quality of life for patients during treatment, sparing them from adverse effects such as nausea, hair loss, cardiotoxicity, and neuropathy.
The TEODOR Trial design and Objectives
The TEODOR trial employs a randomized controlled design, enrolling patients with early-stage, HR+/HER2- breast cancer. Participants will be randomized into two arms. One arm will receive additional endocrine therapy,while the control arm will proceed with standard chemotherapy. This design is specifically crafted to directly compare the efficacy of these two distinct treatment strategies within a carefully selected patient population.
The primary endpoint of the TEODOR trial is the rate of neoadjuvant therapy response. This crucial metric will be evaluated using two established indicators: pathological complete response (pCR) and the modified Preoperative Endocrine Prognostic Index (PEPI) score.These measures are vital for assessing the effectiveness of the treatment and the potential benefits of a personalized approach.Beyond the primary endpoint, the study will also meticulously track secondary endpoints. These include critical long-term outcomes such as breast cancer recurrence rates and overall survival. Monitoring these factors is essential for confirming the durability and safety of the endocrine-only treatment strategy, providing a comprehensive understanding of its long-term impact.
Expert Insights and Future Implications
Michael Gnant, MD, FACS, FEBS, President of the ABCSG and Principal Investigator of the TEODOR trial, emphasized the studyS core mission: “TEODOR is designed to examine whether we can use endocrine responsiveness and ctDNA status to optimize systemic therapy in the neoadjuvant setting. This study marks a critical step toward more personalized medicine, leveraging the latest technologies to improve patient care.”
angel rodriguez, MD, Medical Director of Oncology at Natera, echoed this sentiment, stating, “With the TEODOR trial, our goal is to identify patients who may be able to safely forgo chemotherapy. We are proud to collaborate with ABCSG on this significant trial, and we hope this study will support the role of Signatera in guiding neoadjuvant therapy in breast cancer.”
The TEODOR trial’s focus on molecular and biological markers underscores a growing trend in oncology to stratify patients more effectively and tailor therapies for maximum efficacy and minimal toxicity. The prospect of a significant number of patients with early-stage, HR+/HER2- breast cancer being able to avoid chemotherapy represents a major clinical advancement, promising improved patient outcomes and a better treatment experience.
References
- natera Announces Launch of ABCSG 61 (“TEODOR”), a randomized Controlled Trial of Signatera™ in Early-Stage Breast Cancer. News release. Natera. July 29, 2025. Accessed August 1, 2025. https://tinyurl.com/yb5tfsby
- ABCSG 61 / TEODOR : Neoadjuvant TrEatment optimization Driven by Circulating Tumor DNA and endOcrine Responsiveness (TEODOR). ClinicalTrials.gov. Updated July 31, 2025. Accessed August 1, 2025. https://clinicaltrials.gov/study/NCT07084558